Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic Claims Clinical, Cost Advantages For Just-Launched Viva CRT-D

This article was originally published in The Gray Sheet

Executive Summary

Viva is the first of Medtronic’s U.S. CRT-Ds to incorporate the proprietary AdaptivCRT algorithm designed to more readily adapt to a patient’s condition and optimize therapy. The firm also launched its Evera ICD last week.

You may also be interested in...



AdaptivCRT Algorithm Put To The Test In Medtronic’s Superiority Trial

The first of a planned 3,000 patients have been enrolled in the AdaptResonse trial of Medtronic’s AdaptivCRT cardiac resynchronization algorithm. Previous studies have shown the algorithm reduces hospitalizations, and Medtronic hopes AdaptResponse will show it reduces mortality and medical interventions.

Medtronic Launches Full-Body MRI-Compatible Defibrillator In Europe

Medtronic announced the European launch its Evera MRI SureScan ICD system, the only implantable defibrillator approved to be compatible with full-body magnetic resonance imaging.

Long-Term Study Demonstrates Benefits Of Medtronic’s AdaptivCRT

Complete results of the Adaptive CRT study released at the Heart Failure Society of America conference confirm that Medtronic’s AdaptivCRT cardiac resynchronization therapy reduces heart failure hospitalizations compared to regular echo-guided biventricular pacing.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT032036

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel